profit from every $100 of sales.
$0$100
BNB Plus
$0.08+2.50% today
-97.6% in 1 year
1-year low $0.081-year high $3.42
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BNB Plus sold, what it kept, and what it did with the cash.
Sales went from $18.2 million in 2022 to $2.14 million in 2025, with -$15.2 million of profit last year.
SalesProfit
BNB Plus vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BNB Plus | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads BNB Plus's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 18 | 13 | 2 | 2 | |
| 5 | 6 | 1 | 1 | |
| -14 | -11 | -14 | -16 | |
| -13 | -10 | -13 | -16 | |
| -8 | -10 | -7 | -15 | |
| -9,741.86 | -10,930.83 | -1,366.42 | -134.23 | |
| 27.8% | 41.4% | 46.1% | 39.3% | |
| -76.9% | -81.9% | -646.7% | -750.9% | |
| -45.5% | -74.4% | -330.9% | -709.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 22 | 14 | 13 | 4 |
| Cash | 15 | 7 | 6 | 2 |
| Total debt | 0 | 1 | 1 | 0 |
| Total liabilities | 9 | 9 | 4 | 2 |
| 13 | 5 | 9 | 2 | |
| 0 | 0 | 0 | 1 | |
| -85.5% | -139.8% | -109.3% | -507.5% | |
| -64.0% | -200.9% | -76.5% | -657.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -9 | -6 | -14 | -13 | |
| 0 | 0 | 0 | 0 | |
| -9 | -6 | -14 | -13 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 0.2×
- 0.2×
- –
- –
- -2,525.1%
- -2,983.4%
- 0.0%
Profitability
- 39.3%
- -750.9%
- -709.5%
- -1,279.9%
- -140.6%
- -206.2%
- -320.3%
- -150.3%
- -144.1%
- 125.9%
Growth
- −51.0%
- –
- –
- –
- +467.5%
Financial health
- -0.1×
- 0.00
- 0.2%
- –
- 2.32
- 2.28
- 0.10
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 870
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.68 | – | – |
| Feb 12, 2026 | -2.08 | – | – |
| Dec 22, 2025 | -3.17 | -22.50 | +85.9% |
| Aug 14, 2025 | 34.00 | -37.50 | +190.7% |
| May 15, 2025 | -15.35 | -45.00 | +65.9% |
| Dec 31, 2024 | -62.81 | -243.75 | +74.2% |
| Sep 30, 2024 | -239.69 | -255.00 | +6.0% |
| Jun 30, 2024 | 1,170.48 | -371.25 | +415.3% |
News
Starwood signals board review of dividend policy while targeting $800m-plus of 2026 legacy asset resolutionsSeeking Alpha · Nov 6, 2026ePlus Inc (PLUS) (Q2 2027) Earnings Call Highlights: Record $1 Billion in Gross Billings and ...Yahoo Finance · Nov 6, 2026Apollo launches European credit platform with €10B-plus lending capacitySeeking Alpha · Nov 2, 2026GE & GM Earnings, Plus Deals, Deals, DealsYahoo Finance · Nov 1, 2026Here's What the S&P 500 Did the Last 2 Times Its Earnings Grew 25%-Plus for 3 Straight QuartersYahoo Finance · Oct 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
73Pass
Philip Fisher
49No pass
Peter Lynch
0No pass
Joel Greenblatt
0No pass
Charlie Munger
47No pass
Terry Smith
40No pass
Questions about BNB Plus
Is BNB Plus a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BNB Plus AI analysis
What does BNB Plus do?
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It is in Biotechnology.
Does BNB Plus pay a dividend?
No. BNB Plus does not pay a dividend at the moment.
Is BNB Plus stock halal?
No. BNB Plus does not pass our halal screen: its debt is 38% of its market value, at or above the 33% limit. How we check
How has BNB Plus stock done over the past year?
Down 97.6% over the past twelve months, to $0.08. It traded between $0.08 and $3.42 and is 97.6% below its high.
Who are BNB Plus's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BNB Plus's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.